Podcast

Speaking Out About Breast Implant-Associated Cancer

Author(s):

Kristie L. Kahl

In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

Imagine overcoming a breast cancer diagnosis and its treatment, yet in choosing reconstructive surgery with textured implants, finding out you may be at risk for a rare type of lymphoma.

Renee Ridgeley found herself in that exact situation.

Following the recent controversy with a Food and Drug Administration panel not banning these implants that are to blame for causing breast implant-associated anaplastic large-cell lymphoma, many women are speaking out about the issue.

In this week’s CURE® Talks Cancer podcast, we spoke with the patient advocate about her own experience and how women can learn more about their reconstruction options.

Related Videos
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Related Content
An expert discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast cancer: © stock.adobe.com
February 19th 2025

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

Ryan Scott
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The FIRCE-1 trial of firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued. | nobeastsofierce - stock.adobe.com.
February 12th 2025

Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma

Ryan Scott
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Dr. Tycel Phillips discusses the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL. | © Digilife - stock.adobe.com
February 11th 2025

FDA Approval of Calquence Combo Brings Optimism in MCL

Ryan Scott
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
Image of Randy Moss Photo credit: Jonathan Bachman - Getty Images
February 7th 2025

Randy Moss Shares Cancer Update, “Squid Game” Star Dies and More

Alex Biese
From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.